Table 6 Comparisons of effect of Methotrexate use
From: Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients
Methotrexate Use | Time from Symptom to Death (months) | P-value |
Yes | 17.0 (2.4-55.0) n = 18 | 0.5154 |
No | 14.0 (0.4-110.0) n = 249 | |
Yes | 17.0 (2.4-55.0) n = 18 | 0.4442 |
No + N/A | 14.0 (0.4-110.0) n = 258 | |
No | 14.0 (0.4-110.0) n = 249 | 0.5887 |
Yes + N/A | 16.0 (1.7-55.0) n = 27 | |
Methotrexate Use | Overall Survival (months) | P-value |
Yes | 15.5 (1.0-44.0) n = 18 | 0.3677 |
No | 11.0 (0.1-96.0) n = 249 | |
Yes | 15.5 (1.0-44.0) n = 18 | 0.3164 |
No + N/A | 10.1 (0.1-96.0) n = 258 | |
No | 11.0 (0.1-96.0) n = 249 | 0.9292 |
Yes + N/A | 10.0 (1.0-44.0) n = 27 | |
Methotrexate Use | Time from Treatment to Death (months) | P-value |
Yes | 13.0 (1.0-44.0) n = 18 | 0.7858 |
No | 10.1 (0.1-96.0) n = 249 | |
Yes | 13.0 (1.0-44.0) n = 18 | 0.7208 |
No + N/A | 10.0 (0.1-96.0) n = 258 | |
No | 10.1 (0.1-96.0) n = 249 | 0.5852 |
Yes + N/A | 9.0 (1.0-44.0) n = 27 |